Aethlon Medical Inc (AEMD) 0.2050 $AEMD
Aethlon Medical Announces Ebola Humanitarian Use Device Submission to the FDA
PR Newswire - Thu Apr 09, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted a Humanitarian Use Device submission to the United States Food and Drug Administration (FDA) to support potential market clearance of the Aethlon Hemopurifier® as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
Aethlon Medical Announces Reverse Stock Split and Nasdaq Listing Submission
PR Newswire - Wed Apr 08, 6:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of the reverse stock split is subject to approval by the Financial Industry Regulatory Authority (FINRA). Upon approval by FINRA, the Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days. We currently anticipate that FINRA will approve the reverse stock split on April 10, 2015, however there can be no assurance that the effectiveness of the reverse stock split will occur on that date.
Aethlon Medical Discloses Head and Neck Cancer Collaboration
PR Newswire - Thu Apr 02, 7:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, disclosed today that its majority owned subsidiary Exosome Sciences, Inc. has entered into a research collaboration with Thomas Jefferson University. The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
Using Cancer to Treat Liver Failure and Insecticides to Filter Viruses from Blood, Crazy or Genius?
ACCESSWIRE - Thu Mar 26, 3:26AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 26, 2015 / Two months ago, Vital Therapies (VTL) announced full enrollment for a pivotal phase 3 trial of its ELAD system. Now that it's fully enrolled, it's only a matter of time before results are announced. What is ELAD? It's essentially an external liver support system for patients with chronic liver disease, or CLD, of which there are over 100,000 cases each year in the US according to the CDC, and which causes over 1 million deaths each year in China due to endemic viral diseases like Hepatitis C. CLD is actually the fifth leading cause of death in the People's Republic.
VTL: 25.69 (-0.46)
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 9.78 (-0.18), CSII: 40.21 (-0.77)
WHO approves rapid test for Ebola
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 6:15AM CST
BCRX: 9.65 (+0.16), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), INO: 9.78 (-0.18), JNJ: 102.06 (+0.73), CMRX: 37.54 (+0.36), NVAX: 8.35 (+0.16), HEB: 0.23 (+0.01), MRK: 57.25 (-0.18), SRPT: 13.85 (-0.21), NLNK: 55.38 (-0.33), ABIO: 0.84 (+0.01), IBIO: 0.90 (-0.15)
SeeThruEquity Issues Quarterly Update Note on Aethlon Medical, Inc.
ACCESSWIRE - Fri Feb 13, 8:00AM CST
New York, NY / ACCESSWIRE / February 13, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update note on Aethlon Medical, Inc. (OTC:AEMD). Aethlon Medical, Inc. ("Aethlon"
is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On February 10, 2015, Aethlon reported results for F3Q15 (ended December 31, 2014). Highlights of the quarter include:
Aethlon Medical, Inc. - A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
PR Newswire - Thu Feb 12, 2:16PM CST
Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier(R)"
ACCESSWIRE - Thu Feb 12, 2:09PM CST
New York, NY / ACCESSWIRE / February 12, 2015 / Aethlon Medical, Inc. (OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens"
ACCESSWIRE - Thu Feb 05, 8:16AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2015 / Aethlon Medical, Inc. (OTCQB: AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Mr. James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical wins US FDA's approval of Ebola treatment protocol with Aethlon Hemopurifier
M2 - Mon Jan 05, 6:17AM CST
Therapeutic devices company Aethlon Medical (Other OTC:AEMD) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a clinical protocol to treat Ebola-infected individuals in the US with the Aethlon Hemopurifier.
Aethlon Medical Announces Approval of Ebola Treatment Protocol
PR Newswire - Fri Jan 02, 6:15AM CST
Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. In the treatment of viral pathogens, the Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:23AM CST
Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study
PR Newswire - Thu Dec 11, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 8.35 (+0.16), NLNK: 55.38 (-0.33), OSUR: 6.80 (+0.02)
Aethlon Medical Inc: Total Scam Or Legit Company?
Matthew Finston - at Seeking Alpha - Mon Dec 08, 2:27PM CST
Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST
JNJ: 102.06 (+0.73), BCRX: 9.65 (+0.16), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), MRK: 57.25 (-0.18), NLNK: 55.38 (-0.33), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), IXJ: 110.52 (+0.93), IRY: 53.53 (+0.38)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.56 (-0.01), BMRN: 122.20 (+0.12), RNA: 18.65 (unch), SRPT: 13.85 (-0.21)
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
PR Newswire - Tue Dec 02, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
Aethlon Medical Announces Ebola Humanitarian Use Device Submission to the FDA
PR Newswire - Thu Apr 09, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted a Humanitarian Use Device submission to the United States Food and Drug Administration (FDA) to support potential market clearance of the Aethlon Hemopurifier® as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
Aethlon Medical Announces Reverse Stock Split and Nasdaq Listing Submission
PR Newswire - Wed Apr 08, 6:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of the reverse stock split is subject to approval by the Financial Industry Regulatory Authority (FINRA). Upon approval by FINRA, the Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days. We currently anticipate that FINRA will approve the reverse stock split on April 10, 2015, however there can be no assurance that the effectiveness of the reverse stock split will occur on that date.
Aethlon Medical Discloses Head and Neck Cancer Collaboration
PR Newswire - Thu Apr 02, 7:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, disclosed today that its majority owned subsidiary Exosome Sciences, Inc. has entered into a research collaboration with Thomas Jefferson University. The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
Using Cancer to Treat Liver Failure and Insecticides to Filter Viruses from Blood, Crazy or Genius?
ACCESSWIRE - Thu Mar 26, 3:26AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 26, 2015 / Two months ago, Vital Therapies (VTL) announced full enrollment for a pivotal phase 3 trial of its ELAD system. Now that it's fully enrolled, it's only a matter of time before results are announced. What is ELAD? It's essentially an external liver support system for patients with chronic liver disease, or CLD, of which there are over 100,000 cases each year in the US according to the CDC, and which causes over 1 million deaths each year in China due to endemic viral diseases like Hepatitis C. CLD is actually the fifth leading cause of death in the People's Republic.
VTL: 25.69 (-0.46)
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 9.78 (-0.18), CSII: 40.21 (-0.77)
WHO approves rapid test for Ebola
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 6:15AM CST
BCRX: 9.65 (+0.16), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), INO: 9.78 (-0.18), JNJ: 102.06 (+0.73), CMRX: 37.54 (+0.36), NVAX: 8.35 (+0.16), HEB: 0.23 (+0.01), MRK: 57.25 (-0.18), SRPT: 13.85 (-0.21), NLNK: 55.38 (-0.33), ABIO: 0.84 (+0.01), IBIO: 0.90 (-0.15)
SeeThruEquity Issues Quarterly Update Note on Aethlon Medical, Inc.
ACCESSWIRE - Fri Feb 13, 8:00AM CST
New York, NY / ACCESSWIRE / February 13, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update note on Aethlon Medical, Inc. (OTC:AEMD). Aethlon Medical, Inc. ("Aethlon"
is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On February 10, 2015, Aethlon reported results for F3Q15 (ended December 31, 2014). Highlights of the quarter include: Aethlon Medical, Inc. - A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
PR Newswire - Thu Feb 12, 2:16PM CST
Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier(R)"
ACCESSWIRE - Thu Feb 12, 2:09PM CST
New York, NY / ACCESSWIRE / February 12, 2015 / Aethlon Medical, Inc. (OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens"
ACCESSWIRE - Thu Feb 05, 8:16AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2015 / Aethlon Medical, Inc. (OTCQB: AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Mr. James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical wins US FDA's approval of Ebola treatment protocol with Aethlon Hemopurifier
M2 - Mon Jan 05, 6:17AM CST
Therapeutic devices company Aethlon Medical (Other OTC:AEMD) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a clinical protocol to treat Ebola-infected individuals in the US with the Aethlon Hemopurifier.
Aethlon Medical Announces Approval of Ebola Treatment Protocol
PR Newswire - Fri Jan 02, 6:15AM CST
Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. In the treatment of viral pathogens, the Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:23AM CST
Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study
PR Newswire - Thu Dec 11, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 8.35 (+0.16), NLNK: 55.38 (-0.33), OSUR: 6.80 (+0.02)
Aethlon Medical Inc: Total Scam Or Legit Company?
Matthew Finston - at Seeking Alpha - Mon Dec 08, 2:27PM CST
Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST
JNJ: 102.06 (+0.73), BCRX: 9.65 (+0.16), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), MRK: 57.25 (-0.18), NLNK: 55.38 (-0.33), TKMR: 18.19 (+0.59), GSK: 48.23 (+0.51), IXJ: 110.52 (+0.93), IRY: 53.53 (+0.38)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.56 (-0.01), BMRN: 122.20 (+0.12), RNA: 18.65 (unch), SRPT: 13.85 (-0.21)
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
PR Newswire - Tue Dec 02, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
